Drugs in Dev. Oncology
Phase I
Denmark 
Lead Product(s) : Stenoparib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allarity’s Stenoparib + Temozolomide Phase 2 in SCLC gets VA Funding
Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of recurrent small cell lung cancer.
Product Name : 2X-121
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Stenoparib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adcendo ApS Gets FDA IND Clearance for Phase I Tiffany-01 Trial of ADCE-T02
Details : ADCE-T02 is a highly differentiated anti-TF ADC, and the first ADC with a Topoisomerase I inhibitor-based linker/payload, being investigated for advanced solid tumors.
Product Name : ADCE-T02
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 26, 2025
ADC Biotech Adds on $135M Series B
Details : The proceeds will be used to advance Company’s first-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs.
Product Name : AMT-754
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 25, 2024
Details : The license agreement aims to develop FT-7051 (renamed P-300), an oral, small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline.
Product Name : P-300
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.
Product Name : TKI258
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Endovion,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The main result of oral SCO-101 potentiates the effects of FOLFIRI. Based on safety data from this first cohort of patients, Data Safety Monitoring Board has recommended to include 3 additional patients at 150 mg SCO-101and FOLFIRI.
Product Name : SCO-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2020
Lead Product(s) : Endovion,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Servier Completes the Acquisition of Symphogen
Details : As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
April 06, 2020
SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells
Details : Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel.
Product Name : SCO-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2020
Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline
Details : Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 04, 2020
Reset All
